Angiogenesis: High-dose aflibercept demonstrates safety, efficacy in treatment of DME
February 28th 2023David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.
APAO 2023: Keralink Trial and efficacy safety of corneal cross-linking for children with Keratoconus
February 25th 2023The Keralink Trial was the first randomized clinical trial that tested the hypothesis that corneal cross-linking (CXL) might decrease keratoconus progression in children compared with the use of spectacles or contact lenses.
Angiogenesis 2023: Uncovering the mystery surrounding geographic atrophy
February 10th 2023In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.
Angiogenesis 2023: Investigators explore use of ophthalmic artery angioplasty to treat AMD
February 10th 2023In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.
The pathophysiology and pathomorphology of corneal ectasia: Part 4
November 14th 2022Corneal cross-linking (CXL) is improving all the time, although all protocols retain the basic requirements for oxygen, riboflavin and UV light. Recent developments mean that CXL at the slit lamp is feasible, which will improve access to the procedure.